Anti-Inflammatory Effect of Dialyzable Leukocyte Extract in Autoimmune Prostatitis: Evaluation in Animal Model

Pérez-Alvarado, Carlos; Gómez, Consuelo; Reyes, Miguel; García, Mario J.; Pérez, Elizabeth; Mora, Carlos Pérez de la; Sánchez, Verónica Adriana Galván; Ishiwara, D. Guillermo Pérez

doi:10.1155/2017/1832853

Cited by 7 publications

(6 citation statements)

References 42 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IFN-γ has been widely recognized as a signature pro-inflammatory cytokine that plays a central role in inflammation, and several studies have suggested a crucial role for IFN-γ in the pathogenesis of experimental prostatitis in animal models 2728. Thus, we have evaluated the serum concentration of the pro-inflammatory cytokine in our carrageenan-induced prostatitis model.…”

Section: Resultsmentioning

confidence: 99%

MicroRNA expression profile in chronic nonbacterial prostatitis revealed by next-generation small RNA sequencing

et al. 2019

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are considered to be involved in the pathogenic initiation and progression of chronic nonbacterial prostatitis (CNP); however, the comprehensive expression profile of dysregulated miRNAs, relevant signaling pathways, and core machineries in CNP have not been fully elucidated. In the current research, CNP rat models were established through the intraprostatic injection of carrageenan into the prostate. Then, next-generation sequencing was performed to explore the miRNA expression profile in CNP. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) bioinformatical analyses were conducted to reveal the enriched biological processes, molecular functions, and cellular components and signaling pathways. As a result, 1224, 1039, and 1029 known miRNAs were annotated in prostate tissues from the blank control (BC), normal saline injection (NS), and carrageenan injection (CAR) groups ( n = 3 for each group), respectively. Among them, 84 miRNAs (CAR vs BC) and 70 miRNAs (CAR vs NS) with significantly different expression levels were identified. Compared with previously reported miRNAs with altered expression in various inflammatory diseases, the majority of deregulated miRNAs in CNP, such as miR-146b-5p, miR-155-5p, miR-150-5p, and miR-139-5p, showed similar expression patterns. Moreover, bioinformatics analyses have enriched mitogen-activated protein kinase (MAPK), cyclic adenosine monophosphate (cAMP), endocytosis, mammalian target of rapamycin (mTOR), and forkhead box O (FoxO) signaling pathways. These pathways were all involved in immune response, which indicates the critical regulatory role of the immune system in CNP initiation and progression. Our investigation has presented a global view of the differentially expressed miRNAs and potential regulatory networks containing their target genes, which may be helpful for identifying the novel mechanisms of miRNAs in immune regulation and effective target-specific theragnosis for CNP.

show abstract

Section: Resultsmentioning

confidence: 99%

MicroRNA expression profile in chronic nonbacterial prostatitis revealed by next-generation small RNA sequencing

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Decrease of inflammatory infiltrates, morphological changes to similar of normal prostate, and prostatein decreased to basal levels was reported in DLE group with decreased CD45 expression and proinflammatory cytokines TNF-α, IFN-γ, IL-6, IL-17. In summary: DLE is able to modulate inflammatory response in experimental autoimmune prostatitis [24].…”

Section: Results -Immunologic and Clinical Responsementioning

confidence: 94%

Untitled

2019

Int J Immunol Immunother

View full text Add to dashboard Cite

Immune Modulating Peptides (IMP) discussed in literature as a universal immunocorrectors with wide areas of usage which balance the immune system without causing global immune suppression or overreaction. The present article aim is to review the effect and drawbacks of IMPs in form of Dialyzable leukocyte Extracts (DLE) or Transfer Factors (TF) during and following chemotherapy, radiotherapy, drugs interactions, cancer response and clinical outcomes in different cases of cancers such as metastatic breast cancer, glioma, prostate cancer, osteosarcoma and others. The considered cases of immune overreaction and IMP's impact include autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and allergic reactions. The most difficult therapeutic decision is to choose the right treatment for patients with cancer and autoimmune diseases as they both attempt to supervise and control the immune system, managing immune cells in opposite sides. As patients with autoimmune disease experience difficulty to stay in such treatment when immune cells stimulated in order to identify and destroy cancer cells the IMP as immunocorrectors become one of the main and only healthy choices. The universal mechanism of IMPs action and the absence of contraindications extend the indications for their use in pediatric practice. This includes the complex treatment of respiratory viral infections, the possibility of using in frequently ill children with clinical signs of immune dysfunction and acute intestinal infections. According to the reports on safety, absence of adverse and side effects along with positive outcome for patients the IMPs considered as valuable immunocorrector.

show abstract

“…En un modelo murino de prostatitis crónica/ síndrome de dolor pélvico, se demostró que el tratamiento con EDLc produce una disminución de la expresión del marcador de la superficie CD45 y de las citocinas proinflamatorias TNF-a, INF-y, IL-6 e IL-7, con lo cual se demuestra la modulación los efectos patológicos de la prostatitis autoinmune experimental (Pérez-Alvarado et al, 2017).…”

Section: Actividad Anticancerígenaunclassified

Extracto dializable de leucocitos: de una visión unimolecular, a considerarlo un medicamento complejo, constituido por péptidos bioactivos beneficiosos para la salud

Mora¹,

Mora²,

Garcí³

et al. 2023

View full text Add to dashboard Cite

Os autores desta obra: 1. Atestam não possuir qualquer interesse comercial que constitua um conflito de interesses em relação ao conteúdo publicado; 2. Declaram que participaram ativamente da construção dos respectivos manuscritos, preferencialmente na: a) Concepção do estudo, e/ou aquisição de dados, e/ou análise e interpretação de dados; b) Elaboração do artigo ou revisão com vistas a tornar o material intelectualmente relevante; c) Aprovação final do manuscrito para submissão.; 3. Certificam que o texto publicado está completamente isento de dados e/ou resultados fraudulentos; 4. Confirmam a citação e a referência correta de todos os dados e de interpretações de dados de outras pesquisas; 5. Reconhecem terem informado todas as fontes de financiamento recebidas para a consecução da pesquisa; 6. Autorizam a edição da obra, que incluem os registros de ficha catalográfica, ISBN, DOI e demais indexadores, projeto visual e criação de capa, diagramação de miolo, assim como lançamento e divulgação da mesma conforme critérios da Atena Editora. DECLARAÇÃO DA EDITORA A Atena Editora declara, para os devidos fins de direito, que: 1. A presente publicação constitui apenas transferência temporária dos direitos autorais, direito sobre a publicação, inclusive não constitui responsabilidade solidária na criação dos manuscritos publicados, nos termos previstos na Lei sobre direitos autorais (Lei 9610/98), no art. 184 do Código Penal e no art. 927 do Código Civil; 2. Autoriza e incentiva os autores a assinarem contratos com repositórios institucionais, com fins exclusivos de divulgação da obra, desde que com o devido reconhecimento de autoria e edição e sem qualquer finalidade comercial; 3. Todos os e-book são open access, desta forma não os comercializa em seu site, sites parceiros, plataformas de ecommerce, ou qualquer outro meio virtual ou físico, portanto, está isenta de repasses de direitos autorais aos autores; 4. Todos os membros do conselho editorial são doutores e vinculados a instituições de ensino superior públicas, conforme recomendação da CAPES para obtenção do Qualis livro; 5. Não cede, comercializa ou autoriza a utilização dos nomes e e-mails dos autores, bem como nenhum outro dado dos mesmos, para qualquer finalidade que não o escopo da divulgação desta obra.

show abstract

Anti-Inflammatory Effect of Dialyzable Leukocyte Extract in Autoimmune Prostatitis: Evaluation in Animal Model

Cited by 7 publications

References 42 publications

MicroRNA expression profile in chronic nonbacterial prostatitis revealed by next-generation small RNA sequencing

MicroRNA expression profile in chronic nonbacterial prostatitis revealed by next-generation small RNA sequencing

Untitled

Extracto dializable de leucocitos: de una visión unimolecular, a considerarlo un medicamento complejo, constituido por péptidos bioactivos beneficiosos para la salud

Contact Info

Product

Resources

About